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Figure 1 Effect of time on exacerbation rates in clinical trials
with regular budesonide treatment (N ¼ 2208).4–6Dahl et al.1 described a large double-blind 6-month study
that compared two fixed-dose regimens of salmeterol/
fluticasone (S/F) and budesonide/formoterol (B/F). The
mean rate of all asthma exacerbations (primary endpoint),
lung function, symptoms and weeks with guideline asthma
control all showed no treatment differences. However,
despite equivalent outcomes, the conclusion of the paper
chose to focus on post hoc analyses claiming ‘‘S/F was found
to be significantly superior to B/F in reducing the rate of
moderate/severe exacerbations with regular, stable dose
treatment’’. We believe this conclusion is not supported by
the balance of evidence.
Firstly, the conclusion is based on one post hoc exacer-
bation analysis performed during the last of three 8-week
intervals, whereas seven other analyses of exacerbations
showed no significant difference between treatments. Three
a priori analyses based on all exacerbations, which are
omitted from the manuscript, provided no evidence of a
trend in favour of S/F but showed that the exacerbation risk
or rate ratios (S/F:B/F) were slightly higher with S/F (41.0)
for the total number of exacerbations, the severity of
exacerbations and the time to first exacerbation.2
Secondly, the authors attempt to justify examining post
hoc only exacerbations requiring oral steroids or hospita-
lisation by suggesting in the discussion that these events
are more clinically relevant.1 Whilst this is true, it is
difficult to explain why the study was originally designed
and powered to examine less relevant events. The post
hoc exacerbation analyses selected only 3% of the data
collected for exacerbations and divided this further by
interval, with each interval including approximately 1% of
the exacerbation data included in the primary analysis.
Severe (requiring hospital admission) and moderate
(requiring oral steroids) exacerbations were pooled. This
post hoc pooling may have been necessary to increase
power (with most data excluded) or it may have been
designed to ensure that hospitalisations (reported at
baseline) were not reported separately by treatment
group. Of the five hospitalisations that occurred, four
(80%) occurred in the S/F group as did six out of seven
(86%) asthma-related serious adverse events.2 Thus, no
data on the most severe asthma events, favouring the B/F
group, were reported in the manuscript.1nt matter & 2006 Published by Elsevier Ltd.
2006.10.025Finally, the post hoc analysis in EXCEL looked at
exacerbations by ‘‘interval’’, but the methodology used is
currently not validated. Guidelines state that the minimum
period for assessing exacerbations should be 6 months.3
These guidelines also suggest that changes in concomitant
therapy, e.g. exacerbation treatment, can make outcomes
less reliable over time. Thus, it is essential for all data from
the point of randomisation to be incorporated in any
exacerbation rate. We have examined the accuracy of rates
assessed by ‘‘interval’’ using data from long-term controlled
trials,4–6 including ‘‘stable dose’’ budesonide 400–800 mg/
daily (this pooled dataset included 700 ‘‘moderate/severe’’
exacerbations compared with 144 in EXCEL). The data
(Fig. 1) shows annualised rates each month (solid line)
compared with the mean annual rate (broken line). Low-to-
moderate dose budesonide reduced the incidence of
‘‘moderate/severe’’ exacerbations over time, and average
rates halved in the final 3 months versus the first 3 months.
However, the data set shows the inaccuracy of assessment
by ‘‘interval’’, i.e. in the first 6 months, each month with a
high rate was often followed by a month with a lower
rate—due possibly to the carry-over effect of exacerbation
treatment. In addition, only two (16%) estimates by
‘‘interval’’ were in close agreement with the mean. Had
we used 8-week intervals, only one in six estimates would
have been in agreement.
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LETTER TO THE EDITOR682In summary, the EXCEL study confirms that both B/F and
(S/F) as fixed-dose regimens deliver equal efficacy on all a
priori analyses. We are surprised that the authors focus their
conclusions on post hoc findings using unvalidated methods
and fail to report all appropriate a priori analyses. Post hoc
analyses can generate interesting hypotheses but they
provide no proof of superiority.
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